X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-11-20 | VIGL | Magovcevic-Liebisch Ivana | Pres, CEO | P - Purchase | $3.75 | +4,000 | 207,687 | +2% | +$15,000 | ||||||
D | 2022-11-18 | VIGL | Papapetropoulos Spyros | Chief Medical Officer | S - Sale+OE | $14.00 | -300 | 4,000 | -7% | -$4,200 | |||||
M | 2022-05-16 | VIGL | Thorp Clay | Dir | P - Purchase | $2.85 | +36,695 | 1,559,030 | +2% | +$104,411 | |||||
2022-05-05 | VIGL | Thackaberry Evan | SVP, Head of Early Development | P - Purchase | $4.00 | +1,500 | 1,500 | New | +$6,000 | ||||||
2022-05-03 | VIGL | Verni Christopher | GC | P - Purchase | $3.77 | +4,000 | 4,000 | New | +$15,074 | ||||||
M | 2022-05-02 | VIGL | Magovcevic-Liebisch Ivana | Pres, CEO | P - Purchase | $3.68 | +5,000 | 203,687 | +3% | +$18,379 | |||||
2022-05-03 | VIGL | Ziolkowski Jennifer Lynn | CFO | P - Purchase | $3.77 | +4,000 | 4,000 | New | +$15,098 | ||||||
2022-05-03 | VIGL | Papapetropoulos Spyros | Chief Medical Officer | P - Purchase | $3.40 | +4,000 | 4,000 | New | +$13,591 |
A | Amended filing |
D | Derivative transaction in filing (usually option exercise) |
E | Error detected in filing |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |